mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)

• Published in: Gastroenterología y hepatología Vol. 46; no. 10; p. 764
• Main Authors: Riveiro-Barciela, Mar, Roade, Luisa, Martínez-Camprecios, Joan, Vidal-González, Judit, Rodríguez-Diez, Basilio, Perelló, Manel, Ortí, Guillermo, Robles-Alonso, Virginia, Berastegui, Cristina, Navarro, Jordi, Martínez-Valle, Fernando, Bilbao, Itxarone, Castells, Lluis, Ventura-Cots, Meritxell, Llaneras, Jordi, Rando-Segura, Ariadna, Forns, Xavier, Lens, Sabela, Prieto, Martín, García-Eliz, María, Imaz, Arkaitz, Rodríguez-Frías, Francisco, Buti, Maria, Esteban, Rafael
• Format: Journal Article
• Language: English
• Published: Spain 01.12.2023
• Subjects: Adult; Hepatitis Antibodies - therapeutic use; Hepatitis E - epidemiology; Hepatitis, Chronic - epidemiology; HIV Infections; Humans; Immunoglobulin G; Immunosuppressive Agents - adverse effects; Liver Cirrhosis - complications; MTOR Inhibitors - adverse effects; MTOR Inhibitors - therapeutic use; Prospective Studies; Risk Factors; RNA, Viral - analysis; Transaminases; Inmunosupresión; Virus de la hepatitis E; Inhibidores de mTOR; Hepatitis E virus; Trasplante de órgano sólido; Chronic hepatitis E; Hepatitis crónica E; Cirrosis hepática; Immunosuppression; mTOR inhibitors; Infección por VIH; HIV infection; Liver cirrhosis; Solid-organ transplant
• ISSN: 0210-5705
• DOI: 10.1016/j.gastrohep.2023.01.010

Chronic hepatitis E virus (HEV) in persons with immune impairment has a progressive course leading to a rapid progression to liver cirrhosis. However, prospective data on chronic HEV is scarce. The aim of this study was to determine the prevalence and risk factors for chronic HEV infection in subjects with immune dysfunction and elevated liver enzymes. CHES is a multicenter prospective study that included adults with elevated transaminases values for at least 6 months and any of these conditions: transplant recipients, HIV infection, haemodialysis, liver cirrhosis, and immunosuppressant therapy. Anti-HEV IgG/IgM (Wantai ELISA) and HEV-RNA by an automated highly sensitive assay (Roche diagnostics) were performed in all subjects. In addition, all participants answered an epidemiological survey. Three hundred and eighty-one patients were included: 131 transplant recipients, 115 cirrhosis, 51 HIV-infected subjects, 87 on immunosuppressants, 4 hemodialysis. Overall, 210 subjects were on immunosuppressants. Anti-HEV IgG was found in 94 (25.6%) subjects with similar rates regardless of the cause for immune impairment. HEV-RNA was positive in 6 (1.6%), all of them transplant recipients, yielding a rate of chronic HEV of 5.8% among solid-organ recipients. In the transplant population, only therapy with mTOR inhibitors was independently associated with risk of chronic HEV, whereas also ALT values impacted in the general model. Despite previous abnormal transaminases values, chronic HEV was only observed among solid-organ recipients. In this population, the rate of chronic HEV was 5.8% and only therapy with mTOR inhibitors was independently associated with chronic hepatitis E.